GoodRx Care AI Visibility Market Strategy Report - ED Treatment Pills

Answer Capsule

GoodRx Care is the strongest placement advancer in the October 2026 ED Treatment Pills benchmark, reaching 51.01% valid recommendation coverage and converting broad visibility into first-position recommendations at a rate approaching the category leaders. The brand holds 69.93% raw mention presence and a 35.47% top-three rate, placing it third in the category behind Hims and Ro. Its clearest win is a rank-one rate of 15.88%, more than double Ro's 9.80%. Its clearest weakness is that it remains 9.77 percentage points behind Hims on valid recommendation coverage despite comparable presence growth. Its clearest opportunity is converting its rising first-position placements into durable shortlist leadership.

Who This Report Is For

This report is for GoodRx Care commercial, marketing, and category strategy leaders who need to understand how AI systems are recommending ED treatment options, where the brand is winning placement, and which prompt and source layers require attention next.

Report Card

Executive Summary

GoodRx Care delivered the most durable commercial movement in the October 2026 ED Treatment Pills benchmark. Valid recommendation coverage rose to 51.01%, up from the July 2026 baseline of 44.0% and up from September 2026, a move the benchmark classified as significant. The brand now sits third in the category, behind Hims at 60.81% and Ro at 55.07%, and within reach of both.

The placement picture is stronger than the coverage picture. GoodRx Care's top-three recommendation rate rose 18.0 points from July, from 17.5% to 35.47%, and its rank-one rate rose 11.9 points, from 4.0% to 15.88%. Both moves were classified as significant. With 151 valid recommendations, 105 top-three placements, and 47 first-position placements in October, GoodRx Care is no longer a presence story alone. It is a recommended-first-choice story.

The brand's raw mention presence rate rose 14.2 points from July, from 55.7% to 69.93%, also significant. That places GoodRx Care well ahead of Lemonaid Health at 36.5% and plushcare at 30.7% on presence, and within striking distance of Ro at 82.4%. The gap to Hims on presence remains wide at 92.6%.

Sentiment is clean. GoodRx Care recorded 173 positive mentions, 34 neutral mentions, and zero negative mentions in October, producing a net sentiment score of 0.8357. That is the second-highest sentiment reading among the leading brands, behind Lemonaid Health at 0.9074 and ahead of Ro at 0.8074 and Hims at 0.8029. No cautionary or negative framing appeared in the qualified observation set.

The strongest platform signal for GoodRx Care is AI Overviews, where the brand recorded a 66.95% valid recommendation coverage rate, a 47.46% top-three rate, and a 23.73% rank-one rate across 118 observations. AI Mode was also strong, with 60.49% coverage and an 18.52% rank-one rate across 81 observations. The weakest platform signal is ChatGPT, where GoodRx Care recorded a 14.29% valid recommendation coverage rate and zero top-three placements across 7 observations, a small sample but a clear gap relative to Hims at 85.71% coverage on the same platform.

The clearest cluster gap is structural. All 296 qualified observations in October fell into the Brand Recommendation cluster. The benchmark carried zero qualified observations in the Pricing and Value cluster and zero in the Multi-Brand Comparison cluster. GoodRx Care's pricing-adjacent positioning cannot be evaluated against competitors in the current public data, and the brand's strongest commercial attributes may not yet be surfacing in the prompt types the benchmark measures.

What GoodRx Care Is Winning

Questions This Section Answers

• Where is GoodRx Care converting AI visibility into first-position recommendations?
• Which platforms and metrics show the brand's strongest recommendation quality?

GoodRx Care's clearest win is first-position recommendation conversion. The brand's rank-one rate of 15.88% is more than double Ro's 9.80% and second only to Hims at 28.38%. Among the three leading brands, GoodRx Care converted the largest share of its coverage into first-position placements relative to its coverage base.

The second win is AI Overviews performance. Across 118 observations on AI Overviews, GoodRx Care recorded 79 valid recommendations, a 66.95% coverage rate, and a 23.73% rank-one rate. That rank-one rate on AI Overviews places GoodRx Care as the second-strongest brand on the platform behind Hims, whose rank-one rate on AI Overviews is 38.98%.

The third win is sentiment quality. With 173 positive mentions, 34 neutral mentions, and zero negative mentions, GoodRx Care recorded a net sentiment score of 0.8357. The brand is being framed positively in every qualified observation where it appears. No cautionary, comparative-anchor, or negative framing entered the October dataset.

The fourth win is presence growth. The 14.2-point rise in raw mention presence rate from July to October was the largest presence gain among the top three brands. GoodRx Care is being named more often, recommended more often, and placed first more often, all in the same month.

Where GoodRx Care Has the Clearest AI Visibility Gaps

Questions This Section Answers

• Where is GoodRx Care falling behind Hims on AI recommendation coverage?
• Why is the brand present on Copilot and ChatGPT but not converting into ranked recommendations?
• Which prompt clusters are missing from the benchmark entirely, and what does that mean for pricing-adjacent positioning?

The clearest gap is coverage relative to Hims. GoodRx Care holds 51.01% valid recommendation coverage against Hims at 60.81%, a 9.80-point gap. The gap is narrower than it was at the July baseline, when GoodRx Care stood at 44.0% against Hims at 65.5%, a 21.5-point gap. The direction is correct, but Hims retains the category lead across the full July-to-October window.

The second gap is ChatGPT. Across 7 observations on ChatGPT, GoodRx Care recorded a 14.29% valid recommendation coverage rate and zero top-three placements. Hims recorded 85.71% coverage and a 14.29% rank-one rate on the same platform. The sample is small, and individual placements carry outsized weight, but the pattern suggests GoodRx Care is not yet part of the default ChatGPT shortlist for ED treatment prompts.

The third gap is Copilot. Across 26 observations on Copilot, GoodRx Care recorded a 34.62% valid recommendation coverage rate but zero recommendation value captured, meaning the brand appeared in valid recommendations without rank-eligible placement credit. Ro recorded 30.77% coverage on Copilot with 8 valid recommendations, and Hims recorded 26.92% coverage with 7 valid recommendations. GoodRx Care is present on Copilot but not converting that presence into ranked recommendation credit.

The fourth gap is cluster coverage. The benchmark carried zero qualified observations in the Pricing and Value cluster and zero in the Multi-Brand Comparison cluster. GoodRx Care's pricing-adjacent brand positioning cannot be evaluated in the current public data. If the brand's commercial strength is price transparency and value framing, that strength is not yet measurable in the prompt types the benchmark captures.

Biggest Opportunity

Questions This Section Answers

• Which platforms offer GoodRx Care the clearest path from first-position placements to shortlist leadership?
• What would it take for GoodRx Care to move from third-place challenger to co-leader in ED treatment recommendations?

GoodRx Care's biggest opportunity is converting its rising first-position placements into durable shortlist leadership on AI Overviews and AI Mode. The brand already holds a 23.73% rank-one rate on AI Overviews and an 18.52% rank-one rate on AI Mode. Those are the two platforms where GoodRx Care is closest to Hims and where the brand's coverage-to-placement conversion is strongest.

The path forward is to identify which question themes now produce GoodRx Care at rank one, which leader the brand is displacing on those prompts, and whether those placements are stable across monthly measurement. If the brand can hold first-position placements on AI Overviews and AI Mode while closing the coverage gap on ChatGPT and Copilot, it moves from third-place challenger to shortlist co-leader.

Competitive Landscape

Questions This Section Answers

• How does GoodRx Care's top-three and rank-one rate compare to Hims and Ro?
• Which brands are recommended most often and placed first most often in the ED Treatment Pills category?

Hims holds recommendation-stage strength in the ED Treatment Pills category with 60.81% valid recommendation coverage and a 28.38% rank-one rate. Ro is the strongest challenger at 55.07% coverage, and GoodRx Care sits third at 51.01% coverage with the second-highest rank-one rate in the category.

Average recommended rank covers rank-eligible recommendations only.

GoodRx Care's 35.47% top-three rate places it clearly in the leading tier, 6.76 points behind Ro and 13.18 points behind Hims. Its 15.88% rank-one rate is the second-highest in the category, ahead of Ro by 6.08 points. Its average recommended rank of 2.66 is third-best among brands with meaningful coverage, behind Hims at 2.04 and Ro at 2.47. The table shows a brand that is recommended nearly as often as the leaders and placed first more often than the second-place brand.

Prompt Evidence

AI Overviews / Brand Recommendation Prompt: "What is the most effective ED medicine?" Result: GoodRx Care appeared in a valid recommendation with first-position placement, contributing to its 23.73% rank-one rate on AI Overviews.

ChatGPT / Brand Recommendation Prompt: "What is the best online pharmacy for tirzepatide?" Result: GoodRx Care recorded a positive mention but no top-three placement, reflecting the brand's 14.29% coverage rate and zero rank-one placements on ChatGPT.

AI Mode / Brand Recommendation Prompt: "Which Viagra is best for males?" Result: GoodRx Care appeared in a valid recommendation with strong placement, supporting its 18.52% rank-one rate on AI Mode.

Copilot / Brand Recommendation Prompt: "What's the best online prescription?" Result: GoodRx Care appeared in a valid recommendation but did not receive rank-eligible placement credit, reflecting the brand's presence-without-placement pattern on Copilot.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map GoodRx Care's prompt-level placement patterns across all six AI platforms, identifying which question themes produce first-position recommendations and which competitors the brand displaces on those prompts.

Phase 2: Recommendation Readiness Plan Prioritize the ChatGPT and Copilot gaps, where GoodRx Care is present but not converting presence into ranked recommendation credit, and define the prompt themes where the brand can close the coverage gap to Hims.

Phase 3: Owned Answer Layer Buildout Strengthen the owned content and answer surfaces that AI systems retrieve when forming ED treatment recommendations, with emphasis on the question themes where GoodRx Care already holds first-position placement.

Phase 4: Citation / Authority Layer Development Expand the public evidence layer that AI systems cite for ED treatment recommendations, including the health publisher and brand-owned domains that appear in the top-cited source set.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track GoodRx Care's coverage, top-three rate, rank-one rate, and sentiment month over month to confirm whether the October placement gains hold and whether the ChatGPT and Copilot gaps narrow.

Why This Matters

AI presence alone is not enough. GoodRx Care's October results show a brand that is named often, recommended nearly as often as the category leaders, and placed first more often than the second-place brand. The remaining gap is not visibility. It is coverage on specific platforms and specific prompt types where the brand is present but not yet part of the default shortlist.

The next move is targeted correction of the prompt, page, and citation layers that shape AI recommendations. GoodRx Care already holds the placement profile of a shortlist leader on AI Overviews and AI Mode. Closing the ChatGPT and Copilot gaps, and expanding into the pricing and comparison prompt types the benchmark does not yet measure, is where the brand's next coverage gains are most likely to come from.

Core Metrics

Sentiment Score

Questions This Section Answers

• Why can't unclassified AI mention counts be treated as recommendation wins?
• What is the difference between GoodRx Care's 207 mentions and its 173 positive recommendations?

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For GoodRx Care in October 2026: (173 × 1 + 34 × 0 + 0 × -1) / 207 = 0.8357.

This matters because unclassified mention counts are misleading. A brand can appear in hundreds of AI responses and still lose the recommendation if those appearances are neutral references, cautionary framing, or competitor-anchor comparisons. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, a neutral reference, a cautionary mention, and a competitor-displaced mention are not equal.

Counting all mentions as wins is bad measurement. GoodRx Care's 207 mentions include 34 neutral references that carry no recommendation credit. The brand's 173 positive mentions are the ones that reflect genuine recommendation-stage strength. Classified sentiment is required before interpreting AI visibility, because the difference between 207 mentions and 173 positive recommendations is the difference between presence and persuasion.

Sentiment by Platform

Questions This Section Answers

• On which AI platforms does GoodRx Care receive the strongest positive recommendation framing?
• Where is GoodRx Care present but not recommendation-led, according to sentiment scores?

Methodology

Questions This Section Answers

• What was measured and how were the 296 qualified observations derived?
• Why does the benchmark record change but not establish why change occurred?

1. This report is a benchmark-based analysis of GoodRx Care's AI recommendation visibility in the ED Treatment Pills category, drawing on the LLM Authority Index AI Market Discovery Index for October 2026 and the associated metrics aggregation dataset.
2. The reporting window is October 2026, with comparison to the July 2026 baseline and September 2026 where the benchmark provides those figures.
3. Six AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode. All six registered qualified observations in October 2026.
4. The October run began with 800 source prompt-surface observations carrying 658 unique questions. All 800 mentioned a tracked brand or competitor. 547 were relevant and 253 were irrelevant, yielding 296 qualified benchmark observations.
5. The competitor universe contained 10 tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, plushcare, BlueChew, Rex MD, Blink Health, K Health, and Optum.
6. All 296 qualified observations fell into the Brand Recommendation cluster. The Pricing and Value cluster and the Multi-Brand Comparison cluster carried zero qualified observations in October 2026.
7. Stage 0 extraction captured the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources for each prompt-level observation.
8. A mention is counted when a tracked brand appears in a qualified AI response, regardless of recommendation status. GoodRx Care recorded 207 mentions in October 2026.
9. A valid recommendation is counted when a brand appears in a valid recommendation within a qualified observation. GoodRx Care recorded 151 valid recommendations in October 2026.
10. Brand-level percentages use the 296 qualified observations as the public denominator, not the 800-prompt raw collection.
11. The benchmark records change; it does not establish why change occurred. Source presence is evidence about the information environment and is not automatically proof that a source caused a recommendation.
12. The benchmark does not measure market share, sales, revenue attribution, organic-search ranking performance, social media mention volume, or private and gated channels.

See How AI Is Recommending Your Brand

The public benchmark shows where GoodRx Care is winning placement and where coverage gaps remain. A company-level AI visibility audit maps the prompt, platform, competitor, ranking, sentiment, and evidence-source patterns behind those numbers into a prioritized strategy. It turns the question of where the brand stands into which prompts to win next and what evidence will move that outcome.